Synthesis and Characterization of a Novel Biphenol-Based Gadolinium Complex for Encapsulation in Human Red Blood...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Radiology

Background:

• Gadolinium-based contrast agents (GBCAs) are essential for MRI but raise concerns about toxicity and retention.
• Linear chelates, a type of GBCA, are less stable and pose higher risks.
• Developing safer GBCAs with improved biocompatibility is a critical research area.

Purpose of the Study:

• To synthesize and evaluate a novel gadolinium compound (L-Gd) with enhanced biocompatibility.
• To investigate the feasibility of encapsulating L-Gd within human red blood cells (hRBCs) for targeted delivery.
• To assess the safety and efficacy of L-Gd loaded hRBCs as a potential MRI contrast agent carrier system.

Main Methods:

• Synthesis of a novel gadolinium compound (L-Gd) with a specifically designed ligand.
• In vitro biocompatibility assays using hRBCs, including hemolysis and morphological change assessments.
• Preliminary studies on the encapsulation of L-Gd within hRBCs.

Main Results:

• L-Gd demonstrated high compatibility with hRBCs at specific concentrations, with no significant hemolysis or morphological alterations observed.
• Preliminary encapsulation studies confirmed successful association of L-Gd with hRBCs.
• The L-Gd/hRBC system shows potential as a novel drug delivery platform for MRI contrast agents.

Conclusions:

• RBC-mediated delivery of gadolinium complexes, like the L-Gd system, offers a promising strategy to mitigate gadolinium toxicity and long-term tissue retention.
• Further research is warranted to optimize encapsulation, relaxivity, and in vivo performance for clinical translation.